SYRE

Spyre Therapeutics' stock saw a substantial increase of 427.65% in the past six months and 385.22% over the past year. Key events include the announcement of positive 12-week Part A induction results from its Phase 2 SKYLINE trial for SPY003 in ulcerative colitis on September 8, 2026, which met primary and secondary endpoints and demonstrated a favorable safety profile, completing clinical proof-of-concept for its IBD combinations. Topline results from the rheumatoid arthritis sub-study of the SKYWAY Phase 2 trial of SPY072 showed a statistically significant improvement for the low dose but a smaller-than-expected benefit, shifting focus toward broader autoimmune uses and combinations. The company announced a proposed public offering of its common stock on October 5, 2026, followed by the pricing of a $350 million public offering on October 6, 2026, to fund clinical programs. Inducement awards were granted to non-executive employees on October 2, 2026, and September 4, 2026. Significant insider selling in early Q4 2026, totaling $442.5 million over the past 12 months, has been noted as dampening upward momentum.